[go: up one dir, main page]

AR049418A1 - Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. - Google Patents

Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.

Info

Publication number
AR049418A1
AR049418A1 ARP050100628A ARP050100628A AR049418A1 AR 049418 A1 AR049418 A1 AR 049418A1 AR P050100628 A ARP050100628 A AR P050100628A AR P050100628 A ARP050100628 A AR P050100628A AR 049418 A1 AR049418 A1 AR 049418A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
halo
alkoxy
alkylthio
Prior art date
Application number
ARP050100628A
Other languages
English (en)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AR049418A1 publication Critical patent/AR049418A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos pertenecen a la categoría de heteroarilaminopirazoles utilizados para el tratamiento de la diabetes. Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un derivado de heteroarilaminopirazol de formula (1) donde el resto de formula (2) es un radical anular heterocíclico aromático sustituido seleccionado de los restos de formulas (3); R es H, o alquilo C1-6; R1 es H, alquilo C1-6 sustituido opcionalmente con fenilo, estando dicho fenilo sustituido opcionalmente con halo, o [trialquil C1-4]sililo, alquenilo C3-6, alquinilo C3-6, cicloalquilo C3-6 sustituido opcionalmente con hasta dos sustituyentes seleccionados del grupo formado por alquilo C1-3, CF3 y halo, haloalquilo C1-3, o fenil sustituido opcionalmente con hasta dos sustituyentes seleccionados el grupo constituido por halo, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, haloalquilo C1-3, haloalcoxi C1-3 y ciano; R2 es H, halo, alquilo C1-6, piridilo sustituido opcionalmente con hasta dos sustituyentes seleccionados del grupo constituido por alcoxi C1-6, alquiltio C1-6, halo y alquilo C1-6, fenilo sustituido opcionalmente con hasta dos sustituyentes seleccionados del grupo constituido por alquilo C1-6, alcoxi C1-6, alquiltio C1-6, ciano y halo, pirimidilo, tienilo sustituido opcionalmente con hasta dos sustituyentes seleccionados del grupo constituido por alquilo C1-6, alcoxi C1-6, alquiltio C1- 6, ciano y halo, benzotienilo, sustituido opcionalmente con hasta dos sustituyentes seleccionados del grupo constituido por alquilo C1-6, alcoxi C1-6, alquiltio C1-6, ciano y halo, o furilo sustituido opcionalmente con hasta dos sustituyentes seleccionados del grupo constituido por alquilo C1-6, alcoxi C1-6, alquiltio C1-6, ciano y halo; R3 es alquilo C1-6, cicloalquilo C3-6, haloalquilo C2-3 o fenilo opcionalmente sustituido con más de cuatro sustituyentes seleccionados del grupo constituido por alquilo C1-6 opcionalmente sustituido con un alcoxi C1-4, halo, haloalquilo C1-3, alcoxi C1-6, haloalcoxi C1-3, alquiltio C1-6, y ciano; R4 es alquilo C1-6 opcionalmente sustituido con un alcoxi C1-4, alcoxi C1-6, alquiltio C1-6, haloalquilo C1-3, haloalcoxi C1-3, o halo; n = 0, 1, 2, o 3; X es CO2R7, CONR5R6, o SO2NH2; R5 es H, alquilo C1-6, fenilo opcionalmente sustituido con halo o bencilo opcionalmente sustituido en el anillo fenilo con halo; R6 es H o alquilo C1-6; o R5 y R6, tomados junto con el átomo de N al cual están unidos, pueden formar un anillo de piperidina, morfolina, tiomorfolina o piperazina, dicha piperazina opcionalmente sustituida en el N con alquilo C1-3; R7 es H, alquilo C1-6, bencilo opcionalmente sustituido con hasta dos sustituyentes seleccionados del grupo constituido por halo, alquilo C1-6, alcoxi C1-3, haloalquilo C1-3, haloalcoxi C1-3 y alquiltio C1-6; fenilo opcionalmente sustituido con hasta dos sustituyentes seleccionados de alquilo C1-6, halo, alcoxi C1-6, haloalquilo C1-3, haloalcoxi C1-3 y alquiltio C1-6; y sales aceptables para uso farmacéutico del mismo con la condicion de que el compuesto de formula (1) no sea uno de los compuestos de formulas (4).
ARP050100628A 2004-02-27 2005-02-21 Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. AR049418A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54833104P 2004-02-27 2004-02-27
US57290604P 2004-05-20 2004-05-20

Publications (1)

Publication Number Publication Date
AR049418A1 true AR049418A1 (es) 2006-08-02

Family

ID=34976070

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100628A AR049418A1 (es) 2004-02-27 2005-02-21 Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.

Country Status (17)

Country Link
US (2) US7517878B2 (es)
EP (1) EP1720863A4 (es)
JP (1) JP2007525513A (es)
KR (1) KR20060124727A (es)
AR (1) AR049418A1 (es)
AU (1) AU2005220723A1 (es)
BR (1) BRPI0508051A (es)
CA (1) CA2557527A1 (es)
EC (1) ECSP066883A (es)
IL (1) IL177232A0 (es)
MA (1) MA28479B1 (es)
NO (1) NO20064325L (es)
PE (1) PE20051159A1 (es)
RU (1) RU2006134004A (es)
TW (1) TW200538130A (es)
UY (1) UY28774A1 (es)
WO (1) WO2005086656A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
WO2006065590A2 (en) * 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
AU2006297120B2 (en) * 2005-09-30 2011-05-19 Miikana Therapeutics, Inc. Substituted pyrazole compounds
RU2457207C2 (ru) * 2006-03-24 2012-07-27 Эррэй Биофарма Инк. Активаторы глюкокиназы
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
US8362037B2 (en) * 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
EP2166849A4 (en) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc SUBSTITUTED PYRAZOL COMPOUNDS
WO2009042435A1 (en) 2007-09-21 2009-04-02 Array Biopharma Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102008039083A1 (de) * 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AU2010303567B2 (en) * 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
EP3194377A4 (en) * 2014-09-17 2018-04-18 Epizyme, Inc. Heterocycle substituted amino-pyridine compounds and methods of use thereof
WO2016092559A1 (en) * 2014-12-12 2016-06-16 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives having activity as fungicides
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
KR101725292B1 (ko) * 2016-03-30 2017-04-10 한국과학기술연구원 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
KR102553188B1 (ko) 2016-06-16 2023-07-11 데날리 테라퓨틱스 인크. 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405207A1 (de) * 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors

Also Published As

Publication number Publication date
KR20060124727A (ko) 2006-12-05
TW200538130A (en) 2005-12-01
EP1720863A2 (en) 2006-11-15
AU2005220723A1 (en) 2005-09-22
UY28774A1 (es) 2005-08-31
RU2006134004A (ru) 2008-04-10
NO20064325L (no) 2006-11-22
PE20051159A1 (es) 2006-02-22
US20090209451A1 (en) 2009-08-20
BRPI0508051A (pt) 2007-07-17
US20050192294A1 (en) 2005-09-01
ECSP066883A (es) 2006-11-24
IL177232A0 (en) 2006-12-10
JP2007525513A (ja) 2007-09-06
MA28479B1 (fr) 2007-03-01
US7517878B2 (en) 2009-04-14
CA2557527A1 (en) 2005-09-22
EP1720863A4 (en) 2009-04-22
WO2005086656A3 (en) 2005-12-29
WO2005086656A2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
ATE537169T1 (de) Piperidin- und piperazinderivate als p2x3- antagonisten
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
DOP2010000194A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
AR055071A1 (es) Derivados de pirrolo (3,2 - b) pirimidina. composiciones farmaceuticas.
NI200800036A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR082888A1 (es) Compuestos de piridina para la inhibicion de nampt
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
EA200870362A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR042067A1 (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
EP1845081A4 (en) amide
EA201170096A1 (ru) Замещенные производные пиримидона
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TW200744994A (en) Insecticidal 3-acylaminobenzanilides
EA201000101A1 (ru) Производные пиримидина 934
MY169179A (en) Novel piperidine compound or salt thereof
AR063151A1 (es) Inhibidores de metaloproteasas de matriz
AR059886A1 (es) Derivados de amidas como inhibidores de renina
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии

Legal Events

Date Code Title Description
FB Suspension of granting procedure